This handout photo released by Russian Federal Medical Biological Agency (FMBA) shows the Mir 19 coronavirus medicine developed by the Immunology Institute of the FMBA, in Moscow, Russia. The medicine has been registered by the Russian Healthcare Ministry. The drug selectively suppresses vital coronavirus RNA sequences without affecting the human genome. Editorial use only, no archive, no commercial use.
